Enzo Biochem, Inc. (ENZB)
| Market Cap | 36.59M |
| Revenue (ttm) | 27.47M -17.6% |
| Net Income | -21.08M |
| EPS | -0.40 |
| Shares Out | 52.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 0.10 (14.31%) |
| Ex-Dividend Date | Nov 15, 2024 |
| Volume | 361,752 |
| Open | 0.6901 |
| Previous Close | 0.6875 |
| Day's Range | 0.6901 - 0.6994 |
| 52-Week Range | 0.2520 - 1.1900 |
| Beta | 1.17 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 13, 2025 |
About Enzo Biochem
Enzo Biochem, Inc., a life sciences company, engages in the labeling and detection technologies from DNA to whole cell analysis in the United States and internationally. The company offers labels, dyes, antibodies, genomic probes, immunoassays, biochemicals, and proteins are used to label, detect, and visualize a biological target of interest in drug discovery exploration and drug development process development. Its proprietary products and technologies play roles in translational research and drug development areas, including cell biology, ge... [Read more]
Financial Performance
Financial StatementsNews
Battery Ventures Completes Take-Private of Enzo Biochem
BOSTON--(BUSINESS WIRE)-- #industrialtech--Battery Ventures, a global, technology-focused investment firm, announced the completion of its take-private of Enzo Biochem (“Enzo”), a life-science researc...
ENZO BIOCHEM INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Enzo Biochem, Inc. - ENZB
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Enzo ...
Enzo Biochem, Inc. To be Acquired by Battery Ventures in All-Cash Transaction
Transaction Follows Completion of Comprehensive Strategic Review by Special Committee of the Board to Maximize Shareholder Value
Enzo Biochem Reports Third Quarter Fiscal Year 2025 Results
FARMINGDALE, N.Y., June 16, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (OTCQX: ENZB) (“Enzo” or the “Company”) today announced financial results for the fiscal third quarter ended April 30, 2025.
Enzo Biochem, Inc. Announces Review of Strategic Alternatives after Receiving Multiple Inquiries Regarding a Potential Transaction
Forms Special Committee of the Board to Lead Evaluation of Viable Options for Maximizing Shareholder Value
Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX
FARMINGDALE, N.Y., March 28, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced its intention to voluntarily delist its common stock from The New York St...
Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results
FARMINGDALE, N.Y., March 17, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal second quarter ended January 31, 2025, w...
Enzo Biochem Receives Notice of Non-Compliance with New York Stock Exchange Listing Rules
FARMINGDALE, N.Y, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced that it was notified by the New York Stock Exchange (the “NYSE”) that it is...
Enzo Biochem Reports First Quarter Fiscal Year 2025 Results and Provides a Company Update
FARMINGDALE, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal first quarter ended October 31, 2024.
Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend
FARMINGDALE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal fourth quarter ended July 31, 2024 and th...
Enzo Biochem to pay $4.5 mln for failing to safeguard patient data
Enzo Biochem will pay $4.5 million to settle claims it failed to adequately safeguard personal and private health information of its patients, New York Attorney General Letitia James said on Tuedsay.
Enzo Biochem Reports Third Quarter Fiscal 2024 Results and Provides Business Update
FARMINGDALE, N.Y., June 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal third quarter ended April 30, 2024.
Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business Update
FARMINGDALE, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the second quarter ended January 31, 2024.
Enzo Biochem Reports Results of its Annual Meeting of Shareholders and Officer Appointments
FARMINGDALE, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading life science company, announced the voting results from its Annual Meeting held o...
ENZO BIOCHEM REPORTS FIRST QUARTER FISCAL 2024 RESULTS AND PROVIDES BUSINESS UPDATE
FARMINGDALE, NY, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the first quarter ended October 31, 2023.
Steven J. Pully Appointed to Enzo Biochem's Board of Directors
FARMINGDALE, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “the Company”), a leading life sciences company, announced today that Steven J. Pully has been appointed to...
Enzo Biochem Announces Departure of Hamid Erfanian and Appointment of Kara Cannon as Interim CEO
FARMINGDALE, NY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) announced today that Hamid Erfanian, Chief Executive Officer (CEO), will be resigning his seat on the Board of Direc...
Enzo Biochem Completes Sale of Clinical Laboratory to Labcorp
Significant value unlocked for Enzo shareholders with continued focus on life sciences. FARMINGDALE, NY, July 24, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has clo...
Enzo Biochem Reports Third Quarter Fiscal Year 2023 Financial Results
- Enzo Life Sciences reports revenue of $7.5 million, with margin improvement in Q3 FY23 FARMINGDALE, NY, June 14, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a pioneering biosciences and ...
Federman & Sherwood Investigates Enzo Biochem for Data Breach
OKLAHOMA CITY--(BUSINESS WIRE)-- #DataBreach--The law firm of Federman & Sherwood has initiated an investigation into Enzo Biochem with respect to their recent data breach. On May 30, 2023, Enzo Bioch...
Enzo Biochem says ransomware attack exposed clinical test data of 2.5 million patients
Enzo Biochem, a New York-based biotechnology company, has confirmed that a ransomware attack exposed the clinical test information of almost 2.5 million patients.
Enzo Biochem Reports Significant Progress towards Completing the Clinical Lab Asset Sale
FARMINGDALE, NY, May 22, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), announced today that the preliminary voting results from the Inspector of Election at today's Special Meeting of the S...
Enzo Biochem, Inc. Announces Date of Special Meeting of Shareholders
FARMINGDALE, NY, April 24, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo Biochem” or the “Company”), a leading biosciences and diagnostics company, today announced that its special me...
Enzo Biochem Reports Second Quarter Fiscal Year 2023 Financial Results
- Company entered into an Asset Purchase Agreement for substantially all of the operating assets of the Clinical Labs division
Enzo Biochem Agrees to Sell Clinical Laboratory to Labcorp
Significant value unlocked for Enzo shareholders with continued focus on remaining businesses.